Questcor’s stock fell sharply Friday for the second consecutive day on Citron’s report and the news that the FDA is taking an interest in it. Citron Research said that its lab findings, if endorsed by the FDA, could spell serious trouble for …
Shares of Questcor originally leaped over the 27% premium Mallinckrodt is paying, but the stock has pulled back some. Questcor is something of a one-trick pony. But it is a big trick. The company’s H.P. Acthar injectable gel has been …
Questcor’s stock price shot up almost 15% on the news. Synacthen and Synacthen Depot are available in more than 40 countries outside the US for autoimmune and inflammatory conditions like nephrotic syndrome, rheumatoid diseases, …
The 16% price increase comes on the news that Questcor is being acquired by an Irish specialty-pharmaceutical company, Mallinckrodt, in a deal worth $5.6 billion in cash and stock. It is worth noting, as always in these cases, that …
As of March 31, 2011, Questcor had 61.7 million shares of common stock outstanding, with 4.3 million shares remaining under its common stock repurchase program. Questcor's cash, cash equivalents and short-term investments as of …
As a result of defendants’ false statements, Questcor’s stock traded at artificially inflated prices during the Class …
Questcor shareholders will receive $30.00 per share in cash and 0.897 Mallinckrodt shares for each share of Questcor common stock they own, for a total approximate consideration of $86.10 per Questcor share. Following completion of …
Of this amount, $0.6 million, during the second quarter, and $1.8 million, during the six month period, were related to the Company's Employee Stock Purchase Plan (ESPP). In February 2008, Questcor's Board of Directors approved a …
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) has been a battleground stock for years. Bulls have stood by the strong financial performance of the company, while bears have been clinging to the threat of multiple government investigations …
Questcor's stock leapt nearly 40% during trading yesterday as investors welcomed its $135m-plus purchase of Novartis' rival immune drug Synacthen. The US speciality pharma said it has bought rights to develop Synacthen (tetracosactide) …